PT Kalbe Farma Tbk KLBF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 45.25B
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 9.02
- Price/Sales
- 0.87
- Dividend Yield (Trailing)
- 2.78%
- Dividend Yield (Forward)
- 2.78%
- Dividend Payment Schedule
- Jun
- Total Yield
- 3.35%
Company Profile
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Value
- Total Number of Employees
- 12,806
- Website
- https://www.kalbe.co.id
Valuation
|
Metric
|
KLBF
|
|---|---|
Price/Earnings (Normalized) | 9.02 |
Price/Book Value | 1.34 |
Price/Sales | 0.87 |
Price/Cash Flow | 10.27 |
Price/Earnings
KLBF
Financial Strength
|
Metric
|
KLBF
|
|---|---|
Quick Ratio | 1.78 |
Current Ratio | 3.15 |
Interest Coverage | 170.17 |
Quick Ratio
KLBF
Profitability
|
Metric
|
KLBF
|
|---|---|
Return on Assets (Normalized) | 11.86% |
Return on Equity (Normalized) | 15.70% |
Return on Invested Capital (Normalized) | 14.00% |
Return on Assets
KLBF
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|SRxL&@r | LOCK|s> | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|?b<$Z> | LOCK|@F$ | $635B | |||
| AbbVie Inc
ABBV
| LOCK|qV%#hw | LOCK|$q | $505B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|C<c!>@b | LOCK|Zk | $381B | |||
| Merck & Co Inc
MRK
| LOCK|D>C$wZ! | LOCK|HyX | $358B | |||
| Novartis AG ADR
NVS
| LOCK|?%>d%>P | LOCK|qR | $297B | |||
| AstraZeneca PLC
AZN
| LOCK|@?!&>?t< | LOCK|dbL | $267B | |||
| Amgen Inc
AMGN
| LOCK|!YtH<SM | LOCK|@g | $237B | |||
| Gilead Sciences Inc
GILD
| LOCK|!bFftb< | LOCK|s&t | $193B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|?T#^M! | LOCK|<DB | $172B |
United States